Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ondansetron 4 MG Clear all
Completed Phase 2Phase 3 Interventional

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

NCT02542384
View directory record Official record
Conditions
Post Abdominal Surgery Pain
Interventions
CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Sheffield, Alabama • New Haven, Connecticut • Bradenton, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 1, 2026, 4:41 PM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Results available

Effects of Ondansetron in Obsessive-compulsive and Tic Disorders

NCT03239210
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Tic Disorders, Tourette Syndrome
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Results available

Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting

NCT03297021
View directory record Official record
Conditions
Post-operative Nausea and Vomiting
Interventions
Ondansetron 4 MG, Ondansetron 8mg
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Saphenous Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty

NCT01333943
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Study Group: Experimental, Control Group
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 1, 2026, 4:41 PM EDT
Terminated Phase 3 Interventional Results available

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 4 Interventional

Uncomplicated Nausea and Vomiting in the Emergency Department

NCT00778011
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Metoclopramide
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery

NCT01592708
View directory record Official record
Conditions
Post-operative Nausea, Post-operative Vomiting, Nausea Persistent
Interventions
Antiemetic anesthesia protocol
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

NCT02648490
View directory record Official record
Conditions
Solid Tumour
Interventions
HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor
Drug
Lead sponsor
Henlix, Inc
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

NCT01335542
View directory record Official record
Conditions
Readiness to Discharge
Interventions
Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

NCT00967499
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Ondansetron, Palonosetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Phoenix, Arizona • Laguna Hills, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

NCT01395901
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Florence, Alabama • Sheffield, Alabama • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Results available

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

NCT02657031
View directory record Official record
Conditions
Headache
Interventions
Prochlorperazine, Ketamine, Diphenhydramine, Ondansetron, Normal Saline
Drug
Lead sponsor
University Medical Center of Southern Nevada
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Continuous Subpleural Infusion of Bupivacaine

NCT01566838
View directory record Official record
Conditions
Postoperative Pain
Interventions
Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery

NCT01510379
View directory record Official record
Conditions
Nausea and Vomiting Post-foregut Surgery
Interventions
Reletex, IV ondansetron 4 mg q 6 hours for a total of 4 doses, IV promethazine 25 mg q 6 hours prn, Elixir promethazine 25 mg q 6 hours prn after discharge
Device · Drug
Lead sponsor
Kyle A Perry
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

NCT04606264
View directory record Official record
Conditions
Perioperative Optimization
Interventions
Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1
Drug
Lead sponsor
Jennifer Holder-Murray
Other
Eligibility
18 Years and older
Enrollment
3,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea

NCT00708526
View directory record Official record
Conditions
Hypercapnia
Interventions
standard of care for phase one anesthesia care, Quick Emergence Device
Other · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT02772965
View directory record Official record
Conditions
Pediatric Crohn's Disease
Interventions
Methotrexate, Sugar pill (placebo)
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 20 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

NCT01549652
View directory record Official record
Conditions
Opioid Withdrawal, Physical Dependence
Interventions
Ondansetron, Placebo, Morphine, Naloxone 0.4 mg/70 kg, Naloxone 0.8 mg/70 kg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain

NCT03254459
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Buprenorphine Sublingual Spray, Morphine, Oxycodone Hydrochloride, Zofran
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Pasadena, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Perioperative Ketamine for Pain With Gastric Bypass

NCT03448068
View directory record Official record
Conditions
Laparoscopic Gastric Bypass Surgery, Ketamine
Interventions
Ketamine, Standard therapy
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 69 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

NCT02473042
View directory record Official record
Conditions
Post-Operative Nausea and Vomiting, Breast Cancer
Interventions
Electrical Stimulation, Zofran, Dexamethasone, Phenergan, Pepcid, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 1, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking

NCT00183222
View directory record Official record
Conditions
Alcohol Dependence
Interventions
naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Oct 1, 2026, 4:41 PM EDT